NVS » Topics » Excedrin -

This excerpt taken from the NVS 6-K filed Feb 8, 2008.
Excedrin — and expansion in emerging markets, including Eastern Europe and Russia. Rapid growth in Japan following entry in 2007 into the world’s second-largest OTC market. Maintains position as world’s fourth-largest OTC company.

 

Animal Health, ranked No. 5 in its industry, benefits from solid performances in Europe, Asia-Pacific and Latin America. Sankyo Lifetech acquisition in Japan strengthens presence in companion-animal segment.

 

CIBA Vision successfully addresses production challenges for lens-care and contact lens products.

 

52



 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki